U.S. markets open in 5 hours 34 minutes
  • S&P Futures

    4,473.50
    -0.75 (-0.02%)
     
  • Dow Futures

    34,789.00
    +40.00 (+0.12%)
     
  • Nasdaq Futures

    15,511.50
    -6.25 (-0.04%)
     
  • Russell 2000 Futures

    2,233.40
    +0.20 (+0.01%)
     
  • Crude Oil

    72.22
    -0.39 (-0.54%)
     
  • Gold

    1,761.30
    +4.60 (+0.26%)
     
  • Silver

    22.93
    +0.14 (+0.60%)
     
  • EUR/USD

    1.1777
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    18.50
    +0.32 (+1.76%)
     
  • GBP/USD

    1.3793
    -0.0003 (-0.02%)
     
  • USD/JPY

    109.9430
    +0.2250 (+0.21%)
     
  • BTC-USD

    47,878.39
    -526.16 (-1.09%)
     
  • CMC Crypto 200

    1,223.41
    -9.88 (-0.80%)
     
  • FTSE 100

    7,044.17
    +16.69 (+0.24%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Here's Why Myovant Sciences Stock Is Falling Today

·2 min read
Here's Why Myovant Sciences Stock Is Falling Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Myovant Sciences (NYSE: MYOV) stock is losing ground after the company reported earnings for its fiscal first quarter, the three-month period ended June 30, 2021. Investors upset about net product sales that weren't very impressive led the stock 12.5% lower this morning. Sales of products containing Myovant's gonadotropin-releasing hormone (GnRH) receptor antagonist, Orgovyx (relugolix), weren't as impressive as investors were expecting.